WO2004098599A3 - Proton pump inhibitors for the treatment of lower abdominal disorders - Google Patents

Proton pump inhibitors for the treatment of lower abdominal disorders Download PDF

Info

Publication number
WO2004098599A3
WO2004098599A3 PCT/EP2004/050694 EP2004050694W WO2004098599A3 WO 2004098599 A3 WO2004098599 A3 WO 2004098599A3 EP 2004050694 W EP2004050694 W EP 2004050694W WO 2004098599 A3 WO2004098599 A3 WO 2004098599A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
proton pump
lower abdominal
pump inhibitors
abdominal disorders
Prior art date
Application number
PCT/EP2004/050694
Other languages
French (fr)
Other versions
WO2004098599A2 (en
Inventor
Ursula Hole
Wolfgang-Alexander Simon
Iris Velten
Original Assignee
Altana Pharma Ag
Ursula Hole
Wolfgang-Alexander Simon
Iris Velten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag, Ursula Hole, Wolfgang-Alexander Simon, Iris Velten filed Critical Altana Pharma Ag
Priority to AU2004237362A priority Critical patent/AU2004237362A1/en
Priority to MXPA05011699A priority patent/MXPA05011699A/en
Priority to CA002524268A priority patent/CA2524268A1/en
Priority to EP04731018A priority patent/EP1660084A2/en
Priority to US10/555,055 priority patent/US20060235053A1/en
Publication of WO2004098599A2 publication Critical patent/WO2004098599A2/en
Publication of WO2004098599A3 publication Critical patent/WO2004098599A3/en
Priority to NO20055563A priority patent/NO20055563L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of pantoprazole in the treatment of lower abdominal disorders.
PCT/EP2004/050694 2003-05-06 2004-05-04 Proton pump inhibitors for the treatment of lower abdominal disorders WO2004098599A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2004237362A AU2004237362A1 (en) 2003-05-06 2004-05-04 Proton pump inhibitors for the treatment of lower abdominal disorders
MXPA05011699A MXPA05011699A (en) 2003-05-06 2004-05-04 Agents for the treatment of lower abdominal disorders.
CA002524268A CA2524268A1 (en) 2003-05-06 2004-05-04 Proton pump inhibitors for the treatment of lower abdominal disorders
EP04731018A EP1660084A2 (en) 2003-05-06 2004-05-04 Proton pump inhibitors for the treatment of lower abdominal disorders
US10/555,055 US20060235053A1 (en) 2003-05-06 2004-05-04 Agents for the treatment of lower abdominal disorders
NO20055563A NO20055563L (en) 2003-05-06 2005-11-24 Means for the treatment of lower abdominal disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03010168 2003-05-06
EP03010168.7 2003-05-06
EP03016362 2003-07-19
EP03016362.0 2003-07-19

Publications (2)

Publication Number Publication Date
WO2004098599A2 WO2004098599A2 (en) 2004-11-18
WO2004098599A3 true WO2004098599A3 (en) 2005-02-03

Family

ID=33436110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/050694 WO2004098599A2 (en) 2003-05-06 2004-05-04 Proton pump inhibitors for the treatment of lower abdominal disorders

Country Status (7)

Country Link
US (1) US20060235053A1 (en)
EP (1) EP1660084A2 (en)
AU (1) AU2004237362A1 (en)
CA (1) CA2524268A1 (en)
MX (1) MXPA05011699A (en)
NO (1) NO20055563L (en)
WO (1) WO2004098599A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
CA2635272C (en) 2006-01-27 2016-11-29 Yale University Fast acting inhibitor of gastric acid secretion
US8512761B2 (en) * 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
MX2008015967A (en) * 2006-06-15 2009-01-09 Novartis Ag Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury.
JP2011503073A (en) 2007-11-13 2011-01-27 メリテイジ ファーマ，インク． Corticosteroid composition
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
AU2013323476A1 (en) * 2012-09-27 2015-07-30 Claresa LEVETAN Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272876A2 (en) * 1986-12-17 1988-06-29 Glaxo Group Limited Use of heterocyclic derivatives for the manufacture of medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
KR940006531B1 (en) * 1991-08-30 1994-07-21 주식회사 코오롱 Process for preparation of pyridine derivatives
WO2003053221A2 (en) * 2001-12-19 2003-07-03 Eisai Co. Ltd Methods using proton pump inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0695123A4 (en) * 1993-04-27 1996-09-11 Sepracor Inc Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
DE19843413C1 (en) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab New salt form of pantoprazole

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272876A2 (en) * 1986-12-17 1988-06-29 Glaxo Group Limited Use of heterocyclic derivatives for the manufacture of medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
KR940006531B1 (en) * 1991-08-30 1994-07-21 주식회사 코오롱 Process for preparation of pyridine derivatives
WO2003053221A2 (en) * 2001-12-19 2003-07-03 Eisai Co. Ltd Methods using proton pump inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Martindale 32nd edition", 1999, PHARMACEUTICAL PRESS, LONDON, XP002257060 *
DATABASE WPI Section Ch Week 199617, Derwent World Patents Index; Class B03, AN 1996-169761, XP002255908 *
DAVE B ET AL: "Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea.", DIGESTIVE DISEASES AND SCIENCES. UNITED STATES SEP 1999, vol. 44, no. 9, September 1999 (1999-09-01), pages 1893 - 1898, XP008022645, ISSN: 0163-2116 *

Also Published As

Publication number Publication date
CA2524268A1 (en) 2004-11-18
NO20055563L (en) 2005-11-24
EP1660084A2 (en) 2006-05-31
MXPA05011699A (en) 2006-01-23
AU2004237362A1 (en) 2004-11-18
WO2004098599A2 (en) 2004-11-18
US20060235053A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2006044825A3 (en) Mitotic kinesin inhibitors and methods of use thereof
WO2010038086A8 (en) P38 map kinase inhibitors
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2005117870A3 (en) Combination of proton pump inhibitor, buffering agent, and prokinetic agent
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2006017384A3 (en) Indazoles useful in treating cardiovascular diseases
NO20055563L (en) Means for the treatment of lower abdominal disorders
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
WO2004074243A3 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
WO2006055871A3 (en) Treatment for multiple sclerosis
ZA200709072B (en) Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
WO2008011478A3 (en) Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
PL373085A1 (en) Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers
TW200716561A (en) P38 inhibitors and methods of use thereof
WO2003094967A3 (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
WO2006042277A3 (en) Extended release compositions of proton pump inhibitors
WO2003043614A3 (en) Reversible proton pump inhibitors for the treatment of airway disorders
WO2005077018A3 (en) Methods of treating skin disorders
WO2005107464A3 (en) Compounds and compositions as cathepsin s inhibitors
WO2003075926A8 (en) Use of proton pump inhibitors for the treatment of airway disorders
WO2005023253A8 (en) Use of pde4 inhibitors for the treatment of diabetes mellitus
WO2004103291A3 (en) Extended release compositions of proton pump inhibitor
WO2008147763A8 (en) Mmp inhibitors and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005/08341

Country of ref document: ZA

Ref document number: 200508341

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/011699

Country of ref document: MX

Ref document number: 2524268

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 543699

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006235053

Country of ref document: US

Ref document number: 10555055

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004237362

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004731018

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004237362

Country of ref document: AU

Date of ref document: 20040504

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004237362

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004731018

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10555055

Country of ref document: US